UK Medical Cannabis Prices Drop 15% as Competition Increases
Average UK medical cannabis flower prices have fallen by approximately 15% over the past 12 months, according to analysis of dispensing data from major UK clinics. The price reduction is driven by increased competition among importers and domestic cultivators, greater volumes from EU-licensed producers (particularly from Germany and the Netherlands), and margin pressure from new market entrants. Patients are benefiting from lower per-gram costs across most popular strains, with some products now available below £8/gram.
UK medical cannabis patients are paying less for their prescriptions than at any point since legalisation, with average flower prices falling approximately 15% over the past 12 months according to analysis of dispensing data compiled by LeafMe and the UK Cannabis Industry Council.
The average price for a gram of prescribed cannabis flower in the UK has fallen from approximately £12.50/gram in May 2025 to approximately £10.60/gram in May 2026. Budget options from EU producers are now available below £8/gram at several UK clinics, while premium single-origin and domestically grown products remain in the £14–£18/gram range.
Factors driving the price reduction:
- Increased competition: The number of MHRA-licensed cannabis importers operating in the UK has grown from 14 to 23 over the past two years, intensifying competition among suppliers
- German and Dutch production volumes: EU-licensed producers, particularly from Germany following its own medical cannabis liberalisation, have significantly increased export volumes to the UK market at competitive prices
- Domestic cultivation: A small but growing number of UK-licensed cultivators (including Grow Pharma and Celadon) are producing domestically, reducing import costs
- Clinic margin compression: New low-cost clinic entrants have pressured established players to reduce overall patient costs to remain competitive
Oil and capsule prices have also fallen, though less dramatically — approximately 8% across the market over the same period.
Industry observers expect further price reductions as global production capacity grows and UK regulatory frameworks mature. Germany's experience suggests that mature markets typically see 50–60% price reductions over a five-to-seven year post-legalisation period as production scales and competition intensifies.
UK patients can compare current prices for specific strains and products across all major clinics using LeafMe's product comparison tool and budget calculator. Reading our full cost breakdown guide will also help you identify where savings are available.
